talecris

The profits of Catalan pharmaceutical company Grífols in 2013 grew by 34.6% over the previous year, reaching €345.6 million, as reported by the multinational to the Spanish Stock Exchange Regulation Authority (CNMV). The turnover of the company, based in Greater Barcelona, amounted to €2.75 billion, representing a 4.6% increase on 2012 figures. The geographical expansion of the pharmaceutical company has helped mitigating the effects of volatility in currencies, especially between the euro and the dollar. The Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) grew by 9.6% compared to 2012 and stood at €864.6 million, driven by an increase in the sales of plasma proteins and the optimization of the expenses for raw materials and manufacturing.

The Catalan pharmaceutical company posted a net profit of €182.2 million between January and June 2013, which represents an increase of 36.9% on the same period of 2012. 92.1% of Grífols sales are made abroad and this figure has reached €1.27 billion, up from 6.2% on the first half of last year. Total turnover stood at €1.38 billion, a 4.9% increase. Furthermore, between April and June, the multinational based in Greater Barcelona obtained its highest ever quarterly sales in absolute terms, which reached €697.1 million and represented a 7.2% increase on the same period of 2012. Last year, Grífols bought out its main competitor in the US, Telecaris, which made the Catalan company one of the main pharmaceutical companies in North America, particularly in the blood-derivate products.

The company, which is based in Greater Barcelona, is the world’s third leader in blood derivatives pharmaceutical products. Last year, it bought out its main competitor in the United States, Talecris. Grífols had a €2.62 billion turnover in 2012 and almost doubled its sales compared to the 2011 figures. The company’s net profit last year quadruples that of 2011. The good results are due to a significant reduction in debt levels and Grífols’ penetration into the United States market. Besides, this week it announced it bought for €37 million the 60% of Progenika Biopharma’s capital, a Basque biotechnology company specialised in the design of diagnostic tests.

The Catalan pharmaceutical company Grifols, the third world leader in the production of blood plasma based technologies, has seen its turnover increase by 15% in the first half of 2012 to €1.32 billion. Its net profit for the first half of 2012 was €133.5 million, seven times that of the previous year. The company’s success is attributed to its wide geographical consumer base and the recent purchase of US based Talecris Plasma Resources.

The Catalan pharmaceutical company is the world’s leader in blood-derived products. After expanding in the United States by purchasing Talecris, Grifols needed a larger headquarters. It moved to three interconnected buildings in Sant Cugat del Vallès, in Barcelona’s Metropolitan Area. From the new facilities, Grifols will investigate stem cells and Alzheimer’s.